PatentAug 13, 2026, 06:12 AM
Alterity Therapeutics Granted New U.S. Patent for ATH434
AI Summary
Alterity Therapeutics announced that the United States Patent and Trademark Office has granted a new composition of matter patent for ATH434, its lead clinical asset. This patent extends protection for ATH434 to at least 2045, significantly enhancing its long-term commercial potential and strengthening its intellectual property portfolio. The new patent enables future development opportunities for ATH434 in Parkinson's disease and other neurodegenerative disorders, in addition to its ongoing Phase 3 development for Multiple System Atrophy.
Key Highlights
- New U.S. composition of matter patent granted for ATH434, Alterity's lead clinical asset.
- Patent extends protection for ATH434 to at least 2045, enhancing its strategic value.
- Strengthens ATH434's intellectual property as it advances toward Phase 3 development in Multiple System Atrophy.
- Enables future development of ATH434 for Parkinson's disease and other neurodegenerative disorders.
- The patent covers a crystalline structure of ATH434 mesylate and methods for treating neurological conditions.
- Expected to be listed in the FDA's Orange Book upon regulatory approval of ATH434.
Price Impact
More from ATHE